Idenix CEO says hepatitis C candidate ‘not available' for exclusive deals

During a conference call late Wednesday, Idenix Pharmaceuticals CEO Ronald Renauld speculated on why its partner on a potential hepatitis C treatment recently bought the rights to another drug targeting the same disease...